Stavudine delivery in an extended release formulation: Will it provide the right in vivo pharmacokinetics — Some key observations

Editor AJP


Saravanakumar et al, (2010) have performed an
extensive study to enable the delivery of stavudine
in a once daily extended release formulation.[1] The
in vitro evaluation has been performed with multiple
formulation options to enable the selection of the
right formulation system that renders once-a-day
delivery of stavudine, ensuring that zero order release
is maintained during the entire duration. As evidenced
by the generated data, the recommended formulation
(F9), appears to release approximately 4% of the drug
load every hour leading to a complete release of the
stavudine drug load by 24 hours.

Full Text:



Saravanakumar M, Venkateshwaramurthy N, Dhachinamoorthi D,

Perumal P. Extended release matrix tablets of stavudine: Formulation

and in vitro evaluation. Asian J Pharma 2010;4:219-23.

Zhou L, Kaul S, Liu-Kreyche P, Tran SB, Espina RR, Warrack BM, et al.

Disposition of [1'-(14)C]stavudine after oral administration to humans.

Drug Metab Dispos 2010;38:655-66.

Monif T, Tippabhotla SK, Garg M, Singla AK Comparative bioavailability/

bioequivalence of two different stavudine 40 mg capsule formulations:

A randomized, 2-way, crossover study in healthy volunteers under

fasting condition. Int J Clin Pharmacol Ther 2007;45:469-74.

Narang VS, Lulla A, Malhotra G, Purandare S. Bioequivalence evaluation

of two marketed brands of stavudine 40 mg capsules in healthy human

South African volunteers. Pharmacol Res 2004;50:511-6.

Waclawski AP, Sinko PJ. Oral absorption of anti-acquired immune

deficiency syndrome nucleoside analogues. 2. Carrier-mediated

intestinal transport of stavudine in rat and rabbit preparations. J Pharm

Sci 1996;85:478-85.

Hasegawa T, Juni K, Saneyoshi M, Kawaguchi T.Intestinal absorption

and first-pass elimination of 2', 3'-dideoxynucleosides following oral

administration in rats. Biol Pharm Bull 1996;19:599-603.

Ghosh A, Bhaumik UK, Bose A, Mandal U, Gowda V, Chatterjee B, et al.

Extended release dosage form of glipizide: Development and validation

of a level A in vitro-in vivo correlation. Biol Pharm Bull 2008;31:1946-51.

Dutta S, Qiu Y, Samara E, Cao G, Granneman GR. Once-a-day extendedrelease

dosage form of divalproex sodium III: Development and

validation of a Level A in vitro-in vivo correlation (IVIVC). J Pharm Sci


Etropolski MS, Okamoto A, Shapiro DY, Rauschkolb C. Dose conversion

between tapentadol immediate and extended release for low back pain.

Pain Physician 2010;13:61-70.

Jullien V, Raïs A, Urien S, Dimet J, Delaugerre C, Bouillon-Pichault M,

Rey E, Pons G, Blanche S, Tréluyer JM. Age-related differences in the

pharmacokinetics of stavudine in 272 children from birth to 16 years:

A population analysis. Br J Clin Pharmacol.2007;64:105-9.



  • There are currently no refbacks.